Clinical significance of pretreatment serum C-reactive protein level in soft tissue sarcoma

Cancer

Volumn 118, Issue 4, 2012, Pages 1055-1061

  Nakamura, Tomoki ^a   Matsumine, Akihiko ^a   Matsubara, Takao ^a   Asanuma, Kunihiro ^a   Uchida, Astumasa ^a   Sudo, Akihiro ^a  

^a MIE UNIVERSITY   (Japan)

Author keywords

C reactive protein; inflammation; interleukin; prognosis; soft tissue sarcoma

Indexed keywords

C REACTIVE PROTEIN; TUMOR MARKER; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER SURVIVAL; CHILD; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; EVENT FREE SURVIVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RETROSPECTIVE STUDY; SCHOOL CHILD; SOFT TISSUE SARCOMA; SURVIVAL RATE; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; CANCER STAGING; CHONDROSARCOMA; DERMATOFIBROSARCOMA PROTUBERANS; FIBROSARCOMA; LEIOMYOSARCOMA; MALIGNANT FIBROUS HISTIOCYTOMA; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; MYXOFIBROSARCOMA; SYNOVIAL SARCOMA; TUMOR CLASSIFICATION; TUMOR LOCALIZATION; WELL DIFFERENTIATED LIPOSARCOMA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; C-REACTIVE PROTEIN; CHILD; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; SARCOMA; SOFT TISSUE NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84856798830     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26353     Document Type: Article

References (29)

1. Castell JV, Gomez-Lechon MJ, David M, Fabra R, Trullenque R, Heinrich PC,. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology. 1990; 12: 1179-1186.
2. Brull DJ, Serrano N, Zito F, et al. Human CRP gene polymorphism influences CRP levels: implications for the prediction and pathogenesis of coronary heart disease. Arterioscler Thromb Vasc Biol. 2003; 23: 2063-2069.
3. Kressel G, Trunz B, Bub A, et al. Systemic and vascular markers of inflammation in relation to metabolic syndrome and insulin resistance in adults with elevated atherosclerosis risk. Atherosclerosis. 2009; 202: 263-271.
4. Betroni AG, Burke GL, Owusu JA, et al. Inflammation and the incidence of type 2 diabetes: the Multi-Ethnic Study of Atherosclerosis (MESA). Diabetes Care. 2010; 33: 804-810.
5. Karakiewicz PI, Hutterer GC, Trinh QD, et al. C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality. A European study of 313 patients. Cancer. 2007; 110: 1241-1247.
6. Kim DK, Oh SY, Kwon HC, et al. Clinical significance of preoperative serum interleulin-6 and C-reactive protein level in operable gastric cancer. BMC Cancer. 2009; 9: 155.
7. Pierce BL, Ballard-Barbash R, Bernstein L, et al. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol. 2009; 27: 3437-3444.
8. McMillian DC, Canna K, McArdle CS,. Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br J Surg. 2003; 90: 215-219.
9. Scott HR, McMillan C, Forrest LM, et al. The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer. Br J Cancer. 2002; 87: 264-267.
10. Stark JR, Li H, Kraft P, et al. Circulating prediagnostic interleukin-6 and C-reactive protein and prostate cancer incidence and mortality. Int J Cancer. 2009; 124: 2683-2689.
11. de Mello J, Struthers L, Turner R, Cooper EH, Giles GR,. Multivariate analyses as aids to diagnosis and assessment of prognosis in gastrointestinal cancer. Br J Cancer. 1983; 48: 341-348.
12. Falconer JS, Fearson KC, Ross JA, et al. Acute-phase protein response and survival duration of patients with pancreatic cancer. Cancer. 1995; 75: 2077-2082.
13. Nazoe T, Saeki H, Sugimachi K,. Significance of preoperative elevation of serum C-reactive protein as an indicator of prognosis in esophageal carcinoma. Am J Surg. 2001; 182: 197-201.
14. Nakanishi H, Araki N, Kudawara I, et al. Clinical implications of serum C-reactive protein levels in malignant fibrous histiocytoma. Int J Cancer. 2002; 99: 167-170.
15. Cormier JN, Pollock RE,. Soft tissue sarcomas. CA Cancer J Clin. 2004; 54: 94-109.
16. Markhede G, Angervall L, Stener B,. A multivariate analysis of the prognosis after surgical treatment of malignant soft-tissue tumors. Cancer. 1982; 49: 1721-1733.
17. Zager GK, Ballo MT, Pisters PWT, et al. Prognostic factors for patients with localized soft-tissue sarcoma treated with conservation surgery and radiation therapy. An analysis of 1225 patients. Cancer. 2003; 97: 2530-2543.
18. Burke HB, Henson DE,. Criteria for prognostic factors and for an enhanced prognostic system. Cancer. 1993; 72: 3131-3135.
19. Coussens LM, Werb Z,. Inflammation and cancer. Nature. 2002; 420: 860-867.
20. Siemes C, Visser LE, Coebergh JW, et al. C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study. J Clin Oncol. 2006; 24: 5216-5222.
21. Ramsey S, Lamb GWA, Aitchison M, McMillan DC,. The longitudinal relationship between circulating concentrations of C-reactive protein, interleukin-6 and interleukin-10 in patients undergoing resection for renal cancer. Br J Cancer. 2006; 95: 1076-1080.
22. Nazoe T, Korenaga D, Futatsugi M, et al. Immunohistochemical expression of C-reactive protein in squamous cell carcinoma of the esophagusâ significance as a tumor maker. Cancer Lett. 2003; 192: 89-95.
23. Rutkowski P, Kaminska J, Kowalska M, Ruka W, Steffen J,. Cytokine serum levels in soft tissue sarcoma patients: correlations with clinico-pathological features and prognosis. Int J Cancer. 2002; 100: 463-471.
24. Wigmore SJ, Fearon KC, Sangster K, et al. Cytokine regulation of constitutive production of interleukin-8 and -6 by human pancreatic cancer cell lines and serum cytokine concentrations in patients with pancreatic cancer. Int J Oncol. 2002; 21: 881-886.
25. Belluco C, Nitti D, Franz M, et al. Interleukin-6 blood level is associated with circulating carcinoembryonic antigen and prognosis in patients with colorectal cancer. Ann Surg Oncol. 2007; 7: 133-138.
26. Tartour E, Dorval T, Mosseri V, et al. Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients. Br J Cancer. 1994; 69: 911-913.
27. Tsukamoto T, Kumanoto Y, Miyao N, Masumori N, Takahashi A, Yanase M,. Interleukin-6 in renal cell carcinoma. J Urol. 1992; 148: 1778-1782.
28. Martin F, Santolaria F, Batista N, et al. Cytokines levels (IL-6 and IFN-Î), acute phase response and nutritional status as prognostic factors in lung cancer. Cytokine. 1999; 11: 80-86.
29. Crumley ABC, McMillan DC, McKerman M, Going JJ, Shearer CJ, Stuart RC,. An elevated C-reactive protein concentration, prior to surgery, predicts poor cancer-specific survival in patients undergoing resection for gastro-oesophageal cancer. Br J Cancer. 2006; 94: 1568-1571.